CURIS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.47 USD | -0.34% |
|
+1.12% | +13.49% |
| Feb. 09 | HC Wainwright Adjusts Price Target on Curis to $26 From $51, Maintains Buy Rating | MT |
| Feb. 08 | Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to Curis' Fourth Qua...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.47
USD
Average target price
93
USD
Spread / Average Target
+542.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.49% | 85.29M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- CRIS Stock
- News Curis, Inc.
- Transcript : Curis, Inc., Q4 2023 Earnings Call, Feb 08, 2024
